Institutional equity analysts tracking Compass Therapeutics generally view the company as an intriguing speculative opportunity due to its targeted oncology therapies and adequate cash position. However, because it lacks commercial product sales and regular revenue, it is best suited for growth-oriented investors comfortable with high-beta clinical risk.